[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
MW Weiner, DP Veitch, PS Aisen, LA Beckett… - Alzheimer's & …, 2017 - Elsevier
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued
development and standardization of methodologies for biomarkers and has provided an …
development and standardization of methodologies for biomarkers and has provided an …
[HTML][HTML] Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
G Klein, P Delmar, N Voyle, S Rehal… - Alzheimer's research & …, 2019 - Springer
Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully
human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor …
human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor …
Molecular biomarkers of Alzheimer's disease: progress and prospects
The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-
amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse …
amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse …
[HTML][HTML] Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Background Inconsistent positivity thresholds, image analysis pipelines, and quantitative
outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) …
outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) …
[HTML][HTML] Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Imaging or tissue biomarker evidence has been introduced into the core diagnostic pathway
for Alzheimer's disease (AD). PET using 18 F-labelled beta-amyloid PET tracers has shown …
for Alzheimer's disease (AD). PET using 18 F-labelled beta-amyloid PET tracers has shown …
Menopause status moderates sex differences in tau burden: a Framingham PET study
Objective Women have a higher lifetime risk of Alzheimer's disease (AD) than men. Among
cognitively normal (CN) older adults, women exhibit elevated tau positron emission …
cognitively normal (CN) older adults, women exhibit elevated tau positron emission …
The worldwide Alzheimer's disease neuroimaging initiative: ADNI‐3 updates and global perspectives
CJ Weber, MC Carrillo, W Jagust… - … Research & Clinical …, 2021 - Wiley Online Library
Abstract The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a
collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's …
collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's …
PETPVE12: an SPM toolbox for partial volume effects correction in brain PET–application to amyloid imaging with AV45-PET
G Gonzalez-Escamilla, C Lange, S Teipel, R Buchert… - Neuroimage, 2017 - Elsevier
Positron emission tomography (PET) allows detecting molecular brain changes in vivo.
However, the accuracy of PET is limited by partial volume effects (PVE) that affects …
However, the accuracy of PET is limited by partial volume effects (PVE) that affects …
Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
K Mullane, M Williams - Biochemical pharmacology, 2020 - Elsevier
Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly
failed in clinical trials. Together with numerous reports that amyloid is present in brains from …
failed in clinical trials. Together with numerous reports that amyloid is present in brains from …